

** Cannibis-based drugmaker's U.S.-listed shares up 11.11 pct at $76.29, snapping a three-day streak of declines ** Company putting together "building...


Cannabis-based drug maker GW Pharmaceuticals blamed higher research and development costs for higher annual losses, knocking its shares. GW, whose fla...


** U.S.-listed shares of the maker of cannabis-based drugs down 4 pct at $68.50 ** Company said its experimental drug failed to meet the main goal in...


* NICE says modest benefit of Sativex does not justify use * GW says "terrible shame" drug unavailable in home country * Sativex already approved in m...


* NICE says modest benefit of Sativex does not justify use * GW says "terrible shame" drug unavailable in home country * Sativex already approved in m...